本帖最后由 老马 于 2012-1-13 21:20 编辑 3 @: Y! Z% }. e4 g
9 o- Z; ]' g$ m
爱必妥和阿瓦斯丁的比较
$ d+ K( O! i- ]" i! s |* b. p
: C7 W, j+ ~: h# r, P# j9 p
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
! z# I( |6 d4 N. x5 g& y9 p0 k3 c
6 ^8 v4 |+ J6 C; \! O3 W
% Q V" L/ W; \7 I% }) o# xhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/* H2 g) ? N5 i1 E% G' A4 M
==================================================
& L) L" A1 k8 F7 @+ gOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)/ t: Z {$ z/ f$ y( Y: |7 L- A/ w
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.. L E+ c2 e/ V3 V
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
% U- u3 n0 j* D) k% G& R
|